<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pleural complications in lung transplantation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pleural complications in lung transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pleural complications in lung transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lorriana Leard, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ramsey R Hachem, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3539448103"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pleural disease is an important consideration in patients undergoing lung transplantation. For some patients being considered as candidates for lung transplant, pre-existing pleural disease may increase their risk of postoperative pleural complications. Even in the absence of pre-existing pleural disease, pleural complications following lung transplantation are common due to disruption of the pleural space at the time of transplant surgery, complications related to rejection of the allograft, and the immunosuppression regimen post-transplant.</p><p>The risk factors for pleural complications and the postoperative pleural complications that develop in patients undergoing lung transplantation will be reviewed here. Issues regarding the selection of candidates for lung transplantation and the physiologic changes that occur following lung transplantation are discussed separately. (See  <a class="medical medical_review" href="/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a> and  <a class="medical medical_review" href="/d/html/4657.html" rel="external">"Physiologic changes following lung transplantation"</a>.)</p><p class="headingAnchor" id="H4251439829"><span class="h1">RISK FACTORS FOR PLEURAL COMPLICATIONS</span><span class="headingEndMark"> — </span>Lung transplant recipients with pre-existing pleural space abnormalities and donor-recipient size mismatch are at increased risk of pleural complications at the time of lung transplant surgery.</p><p class="headingAnchor" id="H3335326024"><span class="h2">Pre-existing pleural space abnormalities</span><span class="headingEndMark"> — </span>Pleural adhesions due to pre-existing pleural disease may increase the risk of intraoperative and postoperative complications following lung transplantation, but is not necessarily considered a contraindication to lung transplantation [<a href="#rid1">1</a>]. At the time of lung transplantation, a recipient's native lung must be completely removed from that thoracic cavity. Pleural adhesions may make it much more difficult to remove the native lung, increasing operative time and placing the patient at increased risk for intraoperative bleeding.</p><p>Pre-existing pleural space abnormalities may be secondary to many different etiologies, such as prior pneumothorax, hemothorax, chylothorax, empyema, or pleural adhesions. Underlying suppurative lung disease and prior surgical lung biopsy can lead to pleural adhesions. In addition, treatment of these pleural space diseases by the placement of chest tubes, pleurodesis, or pleurectomy may further contribute to pleural space abnormalities that may complicate lung transplantation.</p><p>Special consideration may be needed in candidates with underlying diseases that are prone to cause pleural adhesions [<a href="#rid2">2-5</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Emphysema – Pneumothorax, treatment of pneumothorax, and prior thoracic surgery (eg, lung volume reduction surgery) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interstitial lung disease – Lung biopsy and pneumothorax</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cystic fibrosis (CF) and non-CF bronchiectasis – Chronic suppurative lung disease and pneumothorax with or without surgical intervention can cause extensive pleural adhesions </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphangioleiomyomatosis (LAM) – Pneumothorax and chylothorax and their treatment (See  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Lung transplantation'</a>.) </p><p></p><p>The concern is that lysis of pleural adhesions at the time of lung transplant surgery is technically more difficult and may lead to an increased risk of bleeding and a higher transfusion requirement. However, a few small series are at least partially reassuring in this regard [<a href="#rid3">3,4,6-9</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a small series, 16 patients with CF who had a history of pleural interventions to manage pneumothoraces were compared with 16 patients with CF without prior pneumothorax and 16 patients with non-CF lung disease and no history of pneumothorax or pleural procedures [<a href="#rid7">7</a>]. The transfusion requirement was not different among the groups. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 61 patients with LAM who underwent lung transplantation, 79 percent had a history of pneumothorax and 15 percent had a history of chylothorax [<a href="#rid3">3</a>]. Twenty patients had moderate to severe intraoperative hemorrhage related to adhesion lysis, but no intraoperative deaths were reported. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A separate report described the experience with 41 patients with LAM; severe intraoperative hemorrhage due to lysis of extensive adhesions occurred in 21 patients and 13 patients required intraoperative cardiopulmonary bypass [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of lung transplant recipients suggests that pre-existing pleural disease (defined as pleural thickening, plaque, or fibrosis) may be associated with an increased risk of primary graft dysfunction at 0 and 48 hours and worse short term (three month) outcomes, although there was no significant difference in overall survival [<a href="#rid10">10</a>].</p><p></p><p class="headingAnchor" id="H4024962165"><span class="h2">Donor-recipient size mismatches</span><span class="headingEndMark"> — </span>In certain situations, a lung transplant recipient may receive a donor lung that is smaller than the recipient's native lung. This size discrepancy is a risk factor for pleural complications, such as pneumothorax, pleural effusion, and empyema, postoperatively. Specific situations in which size mismatch may occur include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recipients with hyperinflated native lung undergoing transplant with relatively smaller sized donor lung</strong> – Transplantation of undersized lungs has been reported to result in more frequent pleural effusions following lung transplant in patients with COPD [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adult lung transplant recipients receiving pediatric donor lungs</strong> – Size mismatching, particularly at the sites of the vascular and bronchial anastomoses, can predispose recipients to hemothorax due to bleeding at the vascular anastomosis and empyema due to leakage at the bronchial anastomotic site. The undersized lung can leave a residual pleural space with persistent pneumothorax or accumulation of pleural fluid to fill the space, both of which may require thoracentesis or chest tube reinsertion [<a href="#rid12">12</a>]. As an example, in a series of 38 adult recipients of pediatric lung allografts, 10 required chest tube reinsertion for persistent pneumothorax, pleural fluid, or empyema, and four required thoracentesis for recurrent pleural effusion prior to discharge [<a href="#rid12">12</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Living donor lobar transplant recipients</strong> – Similar to adult recipients who receive pediatric donor lungs, recipients of living lobar lung transplantation are likely to have size discrepancies at the site of the vascular and bronchial anastomoses, and also to have smaller overall lung volumes, placing them at increased risk of pleural space complications [<a href="#rid13">13</a>].</p><p></p><p class="headingAnchor" id="H3990413852"><span class="h1">PLEURAL COMPLICATIONS FOLLOWING LUNG TRANSPLANTATION</span><span class="headingEndMark"> — </span>Pleural complications, such as pleural effusion, hemothorax, and pneumothorax, are common complications following lung transplantation, occurring in 22 to 45 percent of lung transplant recipients [<a href="#rid11">11,14</a>]. Most often, these occur in the first couple of weeks after lung transplant, but they occasionally occur later post-transplant. Rarely, empyema, chylothorax or malignant pleural effusions may occur. The development of pleuroparenchymal fibroelastosis (PPFE) in the late post-transplant period is being increasingly recognized as a potential manifestation of Chronic Lung Allograft Dysfunction (CLAD).</p><p class="headingAnchor" id="H1911038007"><span class="h2">Pleural effusions</span><span class="headingEndMark"> — </span>Pleural effusions are very common in the early post-transplant period. Pleural effusions are also observed later post-transplant, but due to different etiologies.</p><p class="headingAnchor" id="H385378556"><span class="h3">Pleural effusions early post-transplant</span><span class="headingEndMark"> — </span>In the early post-lung transplant period, the most likely contributing factors to the accumulation of pleural fluid include increased alveolar capillary permeability, because of allograft ischemia, denervation, and subsequent reperfusion [<a href="#rid15">15</a>], and disruption of lymphatic flow due to severance of allograft lung lymphatics. It has been reported that 100 percent of lung transplant recipients have pleural effusions post-transplant. As an example, in one series of 100 patients, all had ipsilateral pleural effusions after lung transplant [<a href="#rid16">16</a>]. Thus, all patients have chest tubes in place postoperatively to drain the pleural space and diuretics are commonly utilized to try to reduce pleural fluid accumulation [<a href="#rid17">17</a>].</p><p>Postoperative pleural effusions are usually small to moderate in size (<a class="graphic graphic_diagnosticimage graphicRef53151" href="/d/graphic/53151.html" rel="external">image 1</a>), but rarely can be massive [<a href="#rid18">18</a>]. Most resolve with thoracostomy tube drainage within 14 days following transplant, although a small percentage may increase in size over the first three postoperative weeks [<a href="#rid15">15</a>]. Most cells in the effusion are of recipient origin, with donor cells accounting for less than 1 percent of the total pleural cell count by the eighth postoperative day [<a href="#rid19">19</a>].</p><p>The characteristics of pleural effusions without clinical evidence of infection or rejection have been studied following single lung transplant in nine patients [<a href="#rid20">20</a>]. The pleural fluid was initially bloody, exudative, and neutrophil-predominant (<a class="graphic graphic_figure graphicRef65922" href="/d/graphic/65922.html" rel="external">figure 1</a>). Over the next seven days, the percentage of neutrophils and the lactate dehydrogenase (LDH) concentration decreased, while the percentage of macrophages and lymphocytes rose. Resolution of daily pleural fluid output generally paralleled a decrease in pulmonary edema. </p><p>Pleural effusions also may result from abnormalities of the pulmonary venous anastomosis, including stenosis, kinking, or thrombosis. These abnormalities may cause unilateral or bilateral pulmonary edema with pleural effusions. </p><p class="headingAnchor" id="H4211197448"><span class="h3">Pleural effusions late post-transplant</span><span class="headingEndMark"> — </span>Late post-transplant pleural effusions can occur in association with acute cellular rejection, trapped lung from prior pleural inflammation, or malignancy. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute cellular rejection</strong> – Analysis of pleural effusions associated with acute cellular rejection in post-transplant recipients has revealed that the fluid is exudative and often contains more than 90 percent lymphocytes [<a href="#rid21">21</a>]. Pleural effusions may occur with acute lung rejection. However, the presence of a pleural effusion detected by chest computed tomography (CT) has poor sensitivity, specificity, and positive and negative predictive values for the diagnosis of acute lung rejection [<a href="#rid22">22</a>]. A small to moderate sized pleural effusion associated with acute cellular rejection will usually improve within one to two days of treatment of the rejection. The evaluation and treatment of acute lung transplant rejection is discussed separately. (See  <a class="medical medical_review" href="/d/html/4655.html" rel="external">"Evaluation and treatment of acute cellular lung transplant rejection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignancy</strong> – Lung transplant recipients are at increased risk of developing malignancies due to long-term immunosuppressive medication. Pleural metastases and primary pleural mesothelioma may manifest as a pleural effusion, which is often hemorrhagic [<a href="#rid23">23</a>]. Pleural effusion is an uncommon manifestation of posttransplant lymphoproliferative disorder [<a href="#rid24">24,25</a>]. (See  <a class="medical medical_review" href="/d/html/4656.html" rel="external">"Noninfectious complications following lung transplantation", section on 'Malignancy'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary venous anastomosis stenosis or thrombosis</strong> – Although these pulmonary venous anastomosis problems typically occur in the immediate postoperative period, pleural effusions from pulmonary venous abnormalities have been reported more than one year after transplant [<a href="#rid26">26,27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pleural effusion management</strong> – Pleural effusions in lung transplant recipients that do not spontaneously resolve within a short period of time often require drainage as a subset of these effusions can become loculated. There is no consensus on the optimal management strategy of pleural effusions following lung transplant, although thoracentesis alone is often ineffective. Management may require (1) drainage with thoracostomy tube, often with the administration of fibrinolytics, (2) placement of an indwelling pleural catheter, or (3) surgical decortication. The risk of additional procedures and chest tube drainage must be balanced with the risks of the development of lung entrapment potentially necessitating reoperation for decortication or development of a fibrothorax. (See <a class="local">'Pleural fibrosis and pleuroparenchymal fibroelastosis (PPFE)'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thoracostomy tube placement +/- fibrinolytics</strong> – Thoracostomy tube placement with administration of intrapleural fibrinolytics following lung transplant appears to be safe and without increased risk of bleeding or infection [<a href="#rid11">11,14</a>]. Pleurodesis via thoracostomy tube is not recommended in these patients, as their immunosuppressed status blunts the inflammatory response to agents such as talc or <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> and places them at increased risk of empyema [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indwelling pleural catheter placement</strong> – Use of indwelling pleural catheters for persistent pleural effusions has become more common in post lung transplant patients. One retrospective analysis followed 71 lung transplant recipients after placement of indwelling pleural catheters during the first year after transplant (median 60 days post-transplant) [<a href="#rid28">28</a>]. Eight (11 percent) of patients developed a complication, including five (7 percent) with pleural infection comparable to published infection rates in nonimmunosuppressed patient populations. The autopleurodesis rate was very high (85 percent), allowing for catheter removal in most patients between 30 and 90 days after placement. No patient required surgical decortication.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Surgical decortication </strong>– Lung transplant recipients with longstanding pleural effusions are at risk of the development of a fibrothorax and a chronic decrease in allograft function. In a large retrospective single-center case series, 77 patients required surgical decortication following lung transplant; this represented 16 percent of patients with pleural complications and 7 percent of the total lung transplant population [<a href="#rid29">29</a>]. The most common indications for decortication included loculated, persistent, or recurrent pleural effusions (56 percent), fibrothorax (20 percent), empyema (13 percent), and hemothorax (11 percent). Outcomes were overall favorable, with 88 percent of patients achieving full lung expansion following the surgical procedure and an approximately 10 percent improvement in spirometry during the first year after surgery. Approximately 36 percent of patients undergoing decortication experienced a complication (eg, transfusion, prolonged intubation, respiratory failure), 12 percent required repeat thoracic surgical intervention, and the 30-day in-hospital mortality rate was 5 percent.</p><p></p><p class="bulletIndent1">Based on these data, surgical decortication is a reasonable strategy to improve allograft function by re-expanding trapped lung, but it does carry significant perioperative risks. Earlier surgical intervention is recommended in the setting of recurrent effusions despite other measures to avoid the development of a fibrothorax, in which case there is a greater risk of extensive bleeding and lack of meaningful lung expansion.</p><p></p><p class="headingAnchor" id="H1139235156"><span class="h2">Hemothorax</span><span class="headingEndMark"> — </span>Hemothorax typically occurs in the immediate postoperative period. Lung transplant recipients are at increased risk for hemothorax given the need for dissection of vascular adhesions to remove the native lung, which can often result in surface oozing; cardiopulmonary bypass with anticoagulation further increases the risk [<a href="#rid17">17</a>]. Close observation of output from the thoracostomy tubes in the immediate postoperative period is important. When significant blood output is observed, spontaneous cessation is unlikely and the risk of retained blood in the pleural space is an important consideration that must be weighed with risks of another surgical procedure and the likelihood of identifying a source of bleeding that can be addressed with early reoperation. </p><p>Up to 15 percent of lung transplant recipients have been found to have residual blood in the pleural space [<a href="#rid2">2,16</a>]. Retained blood or a residual hemothorax can serve as a nidus for infection or lead to additional pleural complications such as trapped lung or fibrothorax. (See <a class="local">'Pleural fibrosis and pleuroparenchymal fibroelastosis (PPFE)'</a> below.)</p><p class="headingAnchor" id="H185332375"><span class="h2">Pneumothorax</span><span class="headingEndMark"> — </span>Pneumothoraces post-transplant may occur in a variety of settings: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Undersized donor lung</strong> – Initially post-transplant, the implanted donor lung size may be smaller than the thoracic cavity, thus resulting in residual air in the pleural space [<a href="#rid30">30</a>]. These pneumothoraces are usually small, clinically insignificant, and resolve within days to a few weeks. By one week post-transplant, there appears to be no significant difference in pleural complications between recipients of undersized lungs [<a href="#rid31">31</a>]. In a case series, negative pressure drainage of the pleural space in recipients with undersized donor lungs and poor chest wall compliance resulted in detrimental effects (eg, hyperinflation, decreased elastic recoil, increased airway pressure) during positive pressure ventilation [<a href="#rid32">32</a>]. Thus, complete evacuation of residual air in the pleural space in recipients with undersized donor lungs may not be necessary and may be deleterious. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anastomotic leak</strong> – A pneumothorax may result from air leaking from the site of the bronchial or tracheal anastomosis. Any significant air leak should be carefully evaluated by flexible bronchoscopy for dehiscence at the site of the airway anastomosis [<a href="#rid17">17</a>]. Approximately 10 percent of lung transplant recipients have an air-leak lasting more than two weeks after surgery [<a href="#rid2">2</a>]. Virtually all of these air-leaks resolve with tube thoracostomy alone and require no further intervention [<a href="#rid2">2</a>]. However, rarely a pneumothorax may result from dehiscence of the bronchial anastomosis. This is a more serious complication, often requiring urgent intervention, such as stenting. (See  <a class="medical medical_review" href="/d/html/4662.html" rel="external">"Airway complications after lung transplantation", section on 'Bronchial necrosis and dehiscence'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iatrogenic complications</strong> – Lung transplant recipients often undergo multiple bronchoscopic procedures usually with transbronchial biopsies to assess for rejection. A pneumothorax is a well described complication of these procedures, although it may occur less frequently than expected because of postoperative pleural adhesions [<a href="#rid33">33-36</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – Superimposed pathology, such as invasive fungal disease or other lung infection. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease in the native lung</strong> – A pneumothorax may develop due to underlying emphysema or other processes in the native lung of a patient who underwent single lung transplant, especially in patients with obstructive or cystic lung disease. These secondary spontaneous pneumothoraces are rarely treated successfully with tube thoracostomy [<a href="#rid37">37</a>]. Both thoracoscopic talc poudrage and thoracoscopic parietal pleurectomy have been successful [<a href="#rid38">38,39</a>].</p><p></p><p class="headingAnchor" id="H3490501961"><span class="h2">Empyema</span><span class="headingEndMark"> — </span>Pleural space infections or empyemas complicate about 3 to 7 percent of lung transplants, and approximately one-quarter of pleural effusions that develop within 90 days of lung transplantation are infected [<a href="#rid16">16,40,41</a>]. Lung transplant recipients may have a blunted clinical presentation of empyema as a result of their immunosuppressed status, and thus a high clinical suspicion is required for all patients. Pleural fluid analysis should therefore always include bacterial, fungal, and mycobacterial cultures, fungal and mycobacterial polymerase chain reaction (PCR), as well as cell count, LDH, protein, glucose, and triglycerides [<a href="#rid17">17,42</a>]. Other tests, such as pleural fluid adenosine deaminase (ADA) and serum beta-D-glucan and galactomannan may be useful. (See  <a class="medical medical_review" href="/d/html/2462.html" rel="external">"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/15717.html" rel="external">"Diagnosis of invasive aspergillosis", section on 'Diagnostic modalities'</a> and  <a class="medical medical_review" href="/d/html/1395.html" rel="external">"Bacterial infections following lung transplantation"</a> and  <a class="medical medical_review" href="/d/html/1394.html" rel="external">"Fungal infections following lung transplantation"</a>.)</p><p>In a study of 455 lung transplants, fungal, bacterial, and mycobacterial pathogens accounted for 61, 25, and 8 percent of pleural infections, respectively [<a href="#rid40">40</a>]. <em>Candida albicans</em> was the predominant organism. Empyemas secondary to tuberculosis, <em>Scopulariopsis</em>, and <em>Mycoplasma hominis</em> have been described [<a href="#rid40">40,43,44</a>]. Occasionally, unusual organisms can be donor derived [<a href="#rid43">43</a>]. </p><p>Patients with pleural space infections have a significantly diminished one year survival compared to those without infection (67 percent versus 87 percent, respectively) [<a href="#rid40">40</a>]. </p><p class="headingAnchor" id="H4000052337"><span class="h2">Chylothorax</span><span class="headingEndMark"> — </span>Chylothorax is the accumulation of chyle (ie, lymphatic fluid) in the pleural space and may occur as an early or late complication of single or bilateral lung transplantation [<a href="#rid45">45</a>]. This is a rare occurrence, generally having been reported in less than 1 percent of recipients [<a href="#rid2">2,16,17,46</a>]. The fluid is characterized by lymphocytosis, a triglyceride level greater than 110 mg/dL, and the presence of chylomicrons. Chylothorax may occur after lung transplant due to disruption of the thoracic duct or its tributaries with chyle leakage into the pleural space [<a href="#rid45">45</a>]. In patients who undergo lung transplant for lymphangioleiomyomatosis, chylothorax may result from leakage of chylous ascites across the diaphragm or more diffuse leakiness of the thoracic lymphatics [<a href="#rid45">45,47,48</a>]. (See  <a class="medical medical_review" href="/d/html/6696.html" rel="external">"Etiology, clinical presentation, and diagnosis of chylothorax"</a> and  <a class="medical medical_review" href="/d/html/107652.html" rel="external">"Sporadic lymphangioleiomyomatosis: Treatment and prognosis", section on 'Chylothorax and chylous ascites'</a>.)</p><p>Several treatment modalities are utilized for chylothorax, including <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> infusion, pleurodesis, thoracic duct ligation, oral <a class="drug drug_general" data-topicid="8561" href="/d/drug information/8561.html" rel="external">aminocaproic acid</a>, and pleuroperitoneal and pleurovenous shunting [<a href="#rid17">17,48-52</a>]. For patients with chylothorax following lung transplant for lymphangioleiomyomatosis, <a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a> therapy has been utilized successfully to ameliorate the effusion, although initiation of sirolimus should be delayed for three or more months until the airway anastomosis has completely healed [<a href="#rid50">50,51</a>]. (See  <a class="medical medical_review" href="/d/html/16356.html" rel="external">"Management of chylothorax"</a>.) </p><p class="headingAnchor" id="H479661166"><span class="h2">Pleural fibrosis and pleuroparenchymal fibroelastosis (PPFE)</span><span class="headingEndMark"> — </span>The development of pleural fibrosis following lung transplant has been observed for many years [<a href="#rid53">53-56</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pleural fibrosis</strong> – Lung transplant recipients with a hemothorax or longstanding pleural effusion may develop a fibrothorax that can restrict lung expansion and reduce long-term allograft function and survival [<a href="#rid14">14</a>]. The role of decortication was examined in a series of 1039 lung transplant recipients, in whom 84 decortication procedures were performed for persistent or recurrent pleural effusions (56 percent), fibrothorax (20 percent), empyema (13 percent), and hemothorax (11 percent) [<a href="#rid29">29</a>]. Among those who underwent thoracoscopic decortication (52 patients), full lung expansion was achieved in 90 percent. For the group overall, forced expiratory volume in one second increased from 50 to 60 percent of predicted in the first year after decortication and survival was 87, 68, and 48 percent at one, three, and five years, respectively, after decortication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PPFE</strong> – Pleural fibrosis can also represent a form of restrictive CLAD with features of PPFE. An experimental study of heart-lung transplants shed some light on the mechanisms that may be involved [<a href="#rid54">54</a>]. Pleural fibrosis developed in animals who received allografts but not in those who received autografts (their own heart-lung bloc). This observation suggests that chronic rejection, not the surgery, was responsible for the pleural fibrosis. A restrictive phenotype of CLAD, restrictive allograft syndrome, is characterized by (sub)pleural thickening on chest CT scan and pathologic findings of pleural fibrosis and PPFE [<a href="#rid55">55,56</a>]. On computed tomography, the features of PPFE include upper lobe predominant pleural thickening with adjacent areas of subpleural consolidation and volume loss [<a href="#rid57">57</a>]. Histopathologic findings in PPFE include upper lobe pulmonary fibrosis with intra-alveolar fibrosis and alveolar septal elastosis [<a href="#rid57">57</a>]. No proven treatment for PPFE exists. Increasing immunosuppression has been associated with increased risk of infection. Clinical trials are currently ongoing studying the use of the antifibrotic medication <a class="drug drug_general" data-topicid="88424" href="/d/drug information/88424.html" rel="external">pirfenidone</a> [<a href="#rid58">58,59</a>].</p><p></p><p class="headingAnchor" id="H1416982286"><span class="h1">INTERPLEURAL COMMUNICATION</span><span class="headingEndMark"> — </span>Interpleural communication can be a consequence of heart-lung transplantation (HLT) and sequential bilateral lung transplantation performed through bilateral anterolateral thoracotomies and transverse sternotomy (clam-shell) due to severing of the anterior pleural reflections. The interpleural communication allows air or fluid to move between the pleural spaces [<a href="#rid60">60-63</a>]. This phenomenon persists for more than two years after HLT [<a href="#rid61">61,62</a>] and is most likely permanent. (See  <a class="medical medical_review" href="/d/html/117242.html" rel="external">"Clinical presentation and diagnosis of pneumothorax", section on 'Pneumothorax appearance and types'</a>.)</p><p>Awareness of the interpleural communication after transplant is important because pleural disease in these recipients must be managed aggressively.</p><p class="bulletIndent1"><span class="glyph">●</span>Empyemas need to be diagnosed early and drained promptly, so that infected pleural contents do not contaminate the contralateral pleural space.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A tension pneumothorax in such recipients is likely to be bilateral and therefore life-threatening.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A single thoracostomy tube may be sufficient to drain bilateral pneumothoraces when an interpleural communication is present [<a href="#rid24">24,64</a>].</p><p></p><p class="headingAnchor" id="H1177542530"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for pleural complications</strong> – Pre-existing pleural space abnormalities can place lung transplant recipients at increased risk for pleural complications, especially bleeding due to lysis of adhesions at the time of surgery. However, the overall long-term outcome of lung transplantation does not appear to be adversely affected by a previous pleural disease or interventions. Donor size mismatch can lead to pleural problems such as pneumothorax, pleural effusion, and empyema. (See <a class="local">'Risk factors for pleural complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early postoperative pleural effusions</strong> – Following lung transplant, pleural effusions have been reported in up to 100 percent of patients. Potential causes include increased alveolar capillary permeability (because of allograft ischemia, denervation, and subsequent reperfusion) and disruption of lymphatic flow due to severance of allograft lung lymphatics. Most postoperative pleural effusions resolve within 14 days with tube thoracostomy drainage. (See <a class="local">'Pleural effusions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent or recurrent pleural effusions</strong> – Persistent or recurrent pleural effusions may develop post lung transplant, associated with acute cellular rejection. These effusions are typically exudative and lymphocytic (eg, 90 percent lymphocytes). (See <a class="local">'Pleural effusions'</a> above and  <a class="medical medical_review" href="/d/html/4655.html" rel="external">"Evaluation and treatment of acute cellular lung transplant rejection"</a>.) </p><p></p><p class="bulletIndent1">Occasionally, pleural effusions in lung transplant recipients may become loculated, leading to entrapment of the lung allograft. Management may require drainage with thoracostomy tube, indwelling pleural catheter, or surgical decortication. (See <a class="local">'Pleural effusions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemothorax</strong> – Hemothorax can occur in the immediate postoperative period and is usually due to bleeding from adhesions that were lysed when the native lung was removed or from coagulopathy. Blood should be evacuated from the pleural space as completely as possible to avoid compromise of ventilation or later problems with lung entrapment. Early reoperation may be required to stop pleural bleeding. (See <a class="local">'Hemothorax'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumothorax</strong> – Pneumothoraces can result from a variety of etiologies from anastomotic leaks to iatrogenic complications of procedures. Most immediate post-transplant pneumothoraces resolved within a few days to weeks, however a significant air leak should prompt rapid evaluation for anastomotic dehiscence. (See <a class="local">'Pneumothorax'</a> above and  <a class="medical medical_review" href="/d/html/4662.html" rel="external">"Airway complications after lung transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empyema</strong> – Empyema has been associated with increased mortality in post lung transplant recipients, and a high clinical suspicion is required in the evaluation of these immunosuppressed patients. (See <a class="local">'Empyema'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pleural fibrosis and pleuroparenchymal fibroelastosis (PPFE)</strong> – Pleural fibrosis and PPFE may occur in chronic lung rejection as one manifestation of chronic lung allograft dysfunction (CLAD). (See <a class="local">'Pleural fibrosis and pleuroparenchymal fibroelastosis (PPFE)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risks of interpleural communication</strong> – Interpleural communication is typically present after heart-lung transplantation and after sequential bilateral lung transplantation performed through bilateral anterolateral thoracotomies or transverse sternotomy (clam-shell). The significance of this communication is that a tension pneumothorax is likely to be bilateral and pleural space infection can be transmitted to the contralateral side. (See <a class="local">'Interpleural communication'</a> above.)</p><p></p><p class="headingAnchor" id="H3213905536"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Marc A Judson, MD and Steven Sahn, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015; 34:1.</a></li><li><a class="nounderline abstract_t">Herridge MS, de Hoyos AL, Chaparro C, et al. Pleural complications in lung transplant recipients. J Thorac Cardiovasc Surg 1995; 110:22.</a></li><li><a class="nounderline abstract_t">Benden C, Rea F, Behr J, et al. Lung transplantation for lymphangioleiomyomatosis: the European experience. J Heart Lung Transplant 2009; 28:1.</a></li><li><a class="nounderline abstract_t">Reynaud-Gaubert M, Mornex JF, Mal H, et al. Lung transplantation for lymphangioleiomyomatosis: the French experience. Transplantation 2008; 86:515.</a></li><li><a class="nounderline abstract_t">Flume PA, Strange C, Ye X, et al. Pneumothorax in cystic fibrosis. Chest 2005; 128:720.</a></li><li><a class="nounderline abstract_t">Dusmet M, Winton TL, Kesten S, Maurer J. Previous intrapleural procedures do not adversely affect lung transplantation. J Heart Lung Transplant 1996; 15:249.</a></li><li><a class="nounderline abstract_t">Curtis HJ, Bourke SJ, Dark JH, Corris PA. Lung transplantation outcome in cystic fibrosis patients with previous pneumothorax. J Heart Lung Transplant 2005; 24:865.</a></li><li><a class="nounderline abstract_t">Madden BP, Hodson ME, Yacoub MH, et al. Heart-lung transplantation for cystic fibrosis. BMJ 1992; 304:835.</a></li><li><a class="nounderline abstract_t">Shitrit D, Fink G, Sahar G, et al. Successful lung transplantation following lung volume reduction surgery. Thorac Cardiovasc Surg 2003; 51:274.</a></li><li><a class="nounderline abstract_t">Soresi S, Zeriouh M, Sabashnikov A, et al. Extended Recipient Criteria in Lung Transplantation: Impact of Pleural Abnormalities on Primary Graft Dysfunction. Ann Thorac Surg 2016; 101:2112.</a></li><li><a class="nounderline abstract_t">Kao CC, Cuevas JF, Tuthill S, Parulekar AD. Pleural catheter placement and intrapleural fibrinolysis following lung transplantation. Clin Transplant 2019; 33:e13592.</a></li><li><a class="nounderline abstract_t">Keshava HB, Mason DP, Murthy SC, et al. Pediatric donor lungs for adult transplant recipients: feasibility and outcomes. Thorac Cardiovasc Surg 2012; 60:275.</a></li><li><a class="nounderline abstract_t">Backhus LM, Sievers EM, Schenkel FA, et al. Pleural space problems after living lobar transplantation. J Heart Lung Transplant 2005; 24:2086.</a></li><li><a class="nounderline abstract_t">Tang A, Siddiqui HU, Thuita L, et al. Natural History of Pleural Complications After Lung Transplantation. Ann Thorac Surg 2021; 111:407.</a></li><li><a class="nounderline abstract_t">Siegleman SS, Sinha SB, Veith FJ. Pulmonary reimplantation response. Ann Surg 1973; 177:30.</a></li><li><a class="nounderline abstract_t">Ferrer J, Roldan J, Roman A, et al. Acute and chronic pleural complications in lung transplantation. J Heart Lung Transplant 2003; 22:1217.</a></li><li><a class="nounderline abstract_t">Arndt A, Boffa DJ. Pleural space complications associated with lung transplantation. Thorac Surg Clin 2015; 25:87.</a></li><li><a class="nounderline abstract_t">Raju S, Heath BJ, Warren ET, Hardy JD. Single- and double-lung transplantation. Problems and possible solutions. Ann Surg 1990; 211:681.</a></li><li><a class="nounderline abstract_t">Judson MA, Sahn SA, Hahn AB. Origin of pleural cells after lung transplantation: from donor or recipient? Chest 1997; 112:426.</a></li><li><a class="nounderline abstract_t">Judson MA, Handy JR, Sahn SA. Pleural effusions following lung transplantation. Time course, characteristics, and clinical implications. Chest 1996; 109:1190.</a></li><li><a class="nounderline abstract_t">Judson MA, Handy JR, Sahn SA. Pleural effusion from acute lung rejection. Chest 1997; 111:1128.</a></li><li><a class="nounderline abstract_t">Gotway MB, Dawn SK, Sellami D, et al. Acute rejection following lung transplantation: limitations in accuracy of thin-section CT for diagnosis. Radiology 2001; 221:207.</a></li><li><a class="nounderline abstract_t">Chhajed PN, Bubendorf L, Hirsch H, et al. Mesothelioma after lung transplantation. Thorax 2006; 61:916.</a></li><li><a class="nounderline abstract_t">Diez Martinez P, Pakkal M, Prenovault J, et al. Postoperative imaging after lung transplantation. Clin Imaging 2013; 37:617.</a></li><li><a class="nounderline abstract_t">Siegel MJ, Lee EY, Sweet SC, Hildebolt C. CT of posttransplantation lymphoproliferative disorder in pediatric recipients of lung allograft. AJR Am J Roentgenol 2003; 181:1125.</a></li><li><a class="nounderline abstract_t">Liguori C, Schulman LL, Weslow RG, et al. Late pulmonary venous complications after lung transplantation. J Am Soc Echocardiogr 1997; 10:763.</a></li><li><a class="nounderline abstract_t">Jing L, Chen W, Zhai Z, et al. Pulmonary vein stenosis after lung transplantation: a case report and literature review. Ann Transl Med 2021; 9:181.</a></li><li><a class="nounderline abstract_t">Trindade AJ, Lentz RJ, Gannon WD, et al. Safety and utility of indwelling pleural catheters in lung transplant recipients. Clin Transplant 2023; 37:e15056.</a></li><li><a class="nounderline abstract_t">Rappaport JM, Siddiqui HU, Tang A, et al. Pleural space management after lung transplant: Early and late outcomes of pleural decortication. J Heart Lung Transplant 2021; 40:623.</a></li><li><a class="nounderline abstract_t">Griffith BP, Zenati M. The pulmonary donor. Clin Chest Med 1990; 11:217.</a></li><li><a class="nounderline abstract_t">Eberlein M, Arnaoutakis GJ, Yarmus L, et al. The effect of lung size mismatch on complications and resource utilization after bilateral lung transplantation. J Heart Lung Transplant 2012; 31:492.</a></li><li><a class="nounderline abstract_t">Kozower BD, Meyers BF, Ciccone AM, et al. Potential for detrimental hyperinflation after lung transplantation with application of negative pleural pressure to undersized lung grafts. J Thorac Cardiovasc Surg 2003; 125:430.</a></li><li><a class="nounderline abstract_t">Trulock EP. Management of lung transplant rejection. Chest 1993; 103:1566.</a></li><li><a class="nounderline abstract_t">Trulock EP, Ettinger NA, Brunt EM, et al. The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures. Chest 1992; 102:1049.</a></li><li><a class="nounderline abstract_t">Greene CL, Reemtsen B, Polimenakos A, et al. Role of clinically indicated transbronchial lung biopsies in the management of pediatric post-lung transplant patients. Ann Thorac Surg 2008; 86:198.</a></li><li><a class="nounderline abstract_t">McWilliams TJ, Williams TJ, Whitford HM, Snell GI. Surveillance bronchoscopy in lung transplant recipients: risk versus benefit. J Heart Lung Transplant 2008; 27:1203.</a></li><li><a class="nounderline abstract_t">Spaggiari L, Rusca M, Carbognani P, et al. Contralateral spontaneous pneumothorax after single lung transplantation for fibrosis. Acta Biomed Ateneo Parmense 1993; 64:29.</a></li><li class="breakAll">Venuta F, Rendina EA, de Giacomo T, et al. Thoracoscopic treatment of recurrent contralateral pneumothorax after single lung transplantation. J Heart Lung Transplant 1994; 13:555.</li><li><a class="nounderline abstract_t">Waller DA, Conacher ID, Dark JH. Videothoracoscopic pleurectomy after contralateral single-lung transplantation. Ann Thorac Surg 1994; 57:1021.</a></li><li><a class="nounderline abstract_t">Wahidi MM, Willner DA, Snyder LD, et al. Diagnosis and outcome of early pleural space infection following lung transplantation. Chest 2009; 135:484.</a></li><li><a class="nounderline abstract_t">Shields RK, Clancy CJ, Minces LR, et al. Epidemiology and outcomes of deep surgical site infections following lung transplantation. Am J Transplant 2013; 13:2137.</a></li><li><a class="nounderline abstract_t">Mills NL, Boyd AD, Gheranpong C. The significance of bronchial circulation in lung transplantation. J Thorac Cardiovasc Surg 1970; 60:866.</a></li><li><a class="nounderline abstract_t">Shaver CM, Castilho JL, Cohen DN, et al. Fatal Scopulariopsis infection in a lung transplant recipient: lessons of organ procurement. Am J Transplant 2014; 14:2893.</a></li><li><a class="nounderline abstract_t">Hayes D Jr, Diaz-Guzman E, Hoopes CW. Rhodococcus equi infection after lung transplantation. Respir Care 2011; 56:1605.</a></li><li><a class="nounderline abstract_t">Boehler A, Speich R, Russi EW, Weder W. Lung transplantation for lymphangioleiomyomatosis. N Engl J Med 1996; 335:1275.</a></li><li><a class="nounderline abstract_t">Jacob S, Meneses A, Landolfo K, et al. Incidence, Management, and Outcomes of Chylothorax after Lung Transplantation: A Single-center Experience. Cureus 2019; 11:e5190.</a></li><li><a class="nounderline abstract_t">Penketh AR, Higenbottam TW, Hutter J, et al. Clinical experience in the management of pulmonary opportunist infection and rejection in recipients of heart-lung transplants. Thorax 1988; 43:762.</a></li><li><a class="nounderline abstract_t">Ryu JH, Doerr CH, Fisher SD, et al. Chylothorax in lymphangioleiomyomatosis. Chest 2003; 123:623.</a></li><li><a class="nounderline abstract_t">Fremont RD, Milstone AP, Light RW, Ninan M. Chylothoraces after lung transplantation for lymphangioleiomyomatosis: review of the literature and utilization of a pleurovenous shunt. J Heart Lung Transplant 2007; 26:953.</a></li><li><a class="nounderline abstract_t">Ohara T, Oto T, Miyoshi K, et al. Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis. Ann Thorac Surg 2008; 86:e7.</a></li><li><a class="nounderline abstract_t">Sugimoto R, Nakao A, Yamane M, et al. Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation. J Heart Lung Transplant 2008; 27:921.</a></li><li><a class="nounderline abstract_t">Kanou T, Nakagiri T, Minami M, et al. Peritoneovenous shunt for chylous ascites after lung transplantation for lymphangioleiomyomatosis. Transplant Proc 2012; 44:1390.</a></li><li><a class="nounderline abstract_t">Yousem SA, Burke CM, Billingham ME. Pathologic pulmonary alterations in long-term human heart-lung transplantation. Hum Pathol 1985; 16:911.</a></li><li><a class="nounderline abstract_t">Haverich A, Dawkins KD, Baldwin JC, et al. Long-term cardiac and pulmonary histology in primates following combined heart and lung transplantation. Transplantation 1985; 39:356.</a></li><li><a class="nounderline abstract_t">Verleden SE, Ruttens D, Vandermeulen E, et al. Restrictive chronic lung allograft dysfunction: Where are we now? J Heart Lung Transplant 2015; 34:625.</a></li><li><a class="nounderline abstract_t">Ofek E, Sato M, Saito T, et al. Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis. Mod Pathol 2013; 26:350.</a></li><li><a class="nounderline abstract_t">Chua F, Desai SR, Nicholson AG, et al. Pleuroparenchymal Fibroelastosis. A Review of Clinical, Radiological, and Pathological Characteristics. Ann Am Thorac Soc 2019; 16:1351.</a></li><li class="breakAll">Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction (PIRCLAD). ClinicalTrials.gov. 
Available at: https://clinicaltrials.gov/ct2/show/NCT03359863 (Accessed on March 29, 2021).</li><li><a class="nounderline abstract_t">Venado A, Dewey K, Montas G, et al. Safety and tolerability of pirfenidone for restrictive chronic lung allograft dysfunction (pirclad): Interim results. Chest 2020; 158:A2389.</a></li><li><a class="nounderline abstract_t">Engeler CE, Olson PN, Engeler CM, et al. Shifting pneumothorax after heart-lung transplantation. Radiology 1992; 185:715.</a></li><li><a class="nounderline abstract_t">Wittich GR, Kusnick CA, Starnes VA, Lucas DE. Communication between the two pleural cavities after major cardiothoracic surgery: relevance to percutaneous intervention. Radiology 1992; 184:461.</a></li><li><a class="nounderline abstract_t">Paranjpe DV, Wittich GR, Hamid LW, Bergin CJ. Frequency and management of pneumothoraces in heart-lung transplant recipients. Radiology 1994; 190:255.</a></li><li class="breakAll">Sacks EM, Unger EC. Heart-lung transplantation: postoperative pleural effusion. AJR Am J Roentgenol 1990; 154:1344.</li><li><a class="nounderline abstract_t">Ng YL, Paul N, Patsios D, et al. Imaging of lung transplantation: review. AJR Am J Roentgenol 2009; 192:S1.</a></li></ol></div><div id="topicVersionRevision">Topic 4653 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25085497" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7541881" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pleural complications in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19134523" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Lung transplantation for lymphangioleiomyomatosis: the European experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18724219" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Lung transplantation for lymphangioleiomyomatosis: the French experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16100160" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pneumothorax in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8777207" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Previous intrapleural procedures do not adversely affect lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15982615" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lung transplantation outcome in cystic fibrosis patients with previous pneumothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1327362" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Heart-lung transplantation for cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14571344" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Successful lung transplantation following lung volume reduction surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26916718" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Extended Recipient Criteria in Lung Transplantation: Impact of Pleural Abnormalities on Primary Graft Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31095770" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pleural catheter placement and intrapleural fibrinolysis following lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22228089" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pediatric donor lungs for adult transplant recipients: feasibility and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16364854" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pleural space problems after living lobar transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32853567" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Natural History of Pleural Complications After Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4682501" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pulmonary reimplantation response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14585383" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Acute and chronic pleural complications in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25430432" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pleural space complications associated with lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2357131" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Single- and double-lung transplantation. Problems and possible solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9266879" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Origin of pleural cells after lung transplantation: from donor or recipient?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8625665" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pleural effusions following lung transplantation. Time course, characteristics, and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9106602" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pleural effusion from acute lung rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11568342" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Acute rejection following lung transplantation: limitations in accuracy of thin-section CT for diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17008483" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mesothelioma after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23557663" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Postoperative imaging after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14500243" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : CT of posttransplantation lymphoproliferative disorder in pediatric recipients of lung allograft.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9339431" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Late pulmonary venous complications after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33569483" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pulmonary vein stenosis after lung transplantation: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37354125" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Safety and utility of indwelling pleural catheters in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33994081" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pleural space management after lung transplant: Early and late outcomes of pleural decortication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2189657" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The pulmonary donor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22325691" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The effect of lung size mismatch on complications and resource utilization after bilateral lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12579123" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Potential for detrimental hyperinflation after lung transplantation with application of negative pleural pressure to undersized lung grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8486045" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Management of lung transplant rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1327662" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18573423" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Role of clinically indicated transbronchial lung biopsies in the management of pediatric post-lung transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18971092" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Surveillance bronchoscopy in lung transplant recipients: risk versus benefit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8036864" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Contralateral spontaneous pneumothorax after single lung transplantation for fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8036864" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Contralateral spontaneous pneumothorax after single lung transplantation for fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8166502" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Videothoracoscopic pleurectomy after contralateral single-lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19017896" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Diagnosis and outcome of early pleural space infection following lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23710593" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Epidemiology and outcomes of deep surgical site infections following lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4922675" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The significance of bronchial circulation in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25376207" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Fatal Scopulariopsis infection in a lung transplant recipient: lessons of organ procurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21513607" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Rhodococcus equi infection after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8857007" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lung transplantation for lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31341753" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Incidence, Management, and Outcomes of Chylothorax after Lung Transplantation: A Single-center Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2849814" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical experience in the management of pulmonary opportunist infection and rejection in recipients of heart-lung transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576391" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Chylothorax in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17845935" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Chylothoraces after lung transplantation for lymphangioleiomyomatosis: review of the literature and utilization of a pleurovenous shunt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19021963" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18656809" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22664021" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Peritoneovenous shunt for chylous ascites after lung transplantation for lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3928482" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pathologic pulmonary alterations in long-term human heart-lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3920794" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Long-term cardiac and pulmonary histology in primates following combined heart and lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25577564" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Restrictive chronic lung allograft dysfunction: Where are we now?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23018877" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31425665" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pleuroparenchymal Fibroelastosis. A Review of Clinical, Radiological, and Pathological Characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31425665" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pleuroparenchymal Fibroelastosis. A Review of Clinical, Radiological, and Pathological Characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Safety and tolerability of pirfenidone for restrictive chronic lung allograft dysfunction (pirclad): Interim results</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1438751" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Shifting pneumothorax after heart-lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1620848" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Communication between the two pleural cavities after major cardiothoracic surgery: relevance to percutaneous intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8259415" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Frequency and management of pneumothoraces in heart-lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8259415" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Frequency and management of pneumothoraces in heart-lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19234284" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Imaging of lung transplantation: review.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
